Skip to main content
TipRanks
Go Ultimate75% OFF

Core Laboratories (CLB) AI Stock Analysis

224 Followers
CLB

Core Laboratories

(NYSE:CLB)

Select Model
Rating:55Neutral
Price Target:$9.50â–²(4.28% Upside)
Action:reiterated
Date:10/29/26

CLB’s score is primarily supported by improved balance-sheet leverage and positive (recently improving) free cash flow, but is held back by sharp TTM revenue contraction and margin pressure. Technicals add additional downside risk given a negative MACD and price below key moving averages, while valuation is not especially supportive with a 27.6 P/E and low dividend yield. The latest earnings call was neutral: sequential progress and longer-term wins/outlook were offset by flat near-term guidance and ongoing geopolitical disruption.

Positive Factors
Improved Balance SheetMaterial debt reduction and a stronger equity base improve Core Lab’s financial flexibility. Lower leverage can reduce balance-sheet pressure, support continued technology investment, and help the company withstand uneven oilfield activity without relying as heavily on external financing.
Negative Factors
Revenue and Margin ContractionThe sharp TTM revenue decline and lower gross and net margins indicate weakened operating leverage and reduced earnings power. If demand remains uneven, the smaller revenue base may make fixed-cost absorption harder and constrain returns despite the company remaining profitable.

Core Laboratories Key Performance Indicators (KPIs)

Revenue By SegmentShows how different business segments contribute to overall revenue, highlighting which areas drive growth and profitability for Core Laboratories.

$0.00$25.00M$50.00M$75.00M$100.00M$125.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Reservoir Description — historically the larger, steady driver — shows a clear pullback in 2026 after peaking in 2025, while Production Enhancement staged a notable rebound in the latest quarter. That divergence suggests customers are shifting spend toward short‑cycle production work versus longer reservoir studies, increasing near‑term revenue volatility but potentially improving cash conversion and margins if intervention work is higher‑margin. Watch operator capex signals and backlog/pricing to judge whether this is a temporary cycle or a structural shift.

Data provided by:The Fly

Core Laboratories (CLB) vs. SPDR S&P 500 ETF (SPY)

-50%-40%-30%-20%-10%0%10%20%30%CLB-40.34%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$417.45M
Dividend Yield
0.44%
Average Volume (3M)
597.77K
Price to Earnings (P/E)
26.8
Beta (1Y)
1.28
Revenue Growth
-0.15%
EPS Growth
-44.32%
Country
US
Employees
3,300
Sector
Energy
Sector Strength
65
Industry
Oil & Gas Equipment & Services

Core Laboratories Business Overview & Revenue Model

Company Description

Core Laboratories N.V. (CLB) is a global provider to the oil and gas sector, delivering specialized services and products for characterizing subterranean reservoirs and optimizing hydrocarbon extraction. The company's operations are distinctly segmen...

How the Company Makes Money

Core Laboratories makes money by selling specialized technical services and products to oil and gas producers, generally under service contracts and project-based work tied to customers’ exploration, appraisal, development, and production programs. I...

Core Laboratories Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:-13.06%|Next Earnings Date:Feb 03, 2027
Earnings Call SentimentNeutral

The call was balanced. Core Lab reported meaningful sequential improvements in revenue, operating income, margins, product sales and EPS, along with several technology wins, a 5-year contract and expectations for stronger global activity in 2027. However, geopolitical conflicts continued to depress year-over-year service and Reservoir Description results, reduce demand for crude assay work, delay projects, constrain cash flow and create uncertainty. Fourth-quarter revenue is expected to remain relatively flat, making the overall tone neutral despite management's constructive longer-term outlook.

Positive Updates

Sequential Improvement in Overall Operating Performance
Compared with the second quarter of 2026, operational performance improved with higher revenue, operating income, operating margins and earnings per share.

Negative Updates

Geopolitical Conflicts Continued to Disrupt Operations
The ongoing military conflict in the Middle East, along with escalating attacks on energy infrastructure in Russia and Ukraine and evolving sanctions, caused project delays, logistical disruptions, suspended Middle East field operations and delayed product shipments.

Company Guidance

For the fourth quarter 2026, Core Lab expects revenue to remain relatively flat sequentially; Reservoir Description revenue is projected to range from $81 million to $85 million with operating income of $5.1 million to $8.3 million, Production Enhancement revenue is estimated to range from $47.5 million to $49.5 million with operating income of $5.5 million to $6.7 million, and company revenue is projected to range from $128.5 million to $134.5 million with operating income of $10.7 million to $15.1 million, yielding operating margins of 10%, while EPS is expected to range from $0.12 to $0.20; guidance excludes gains and losses in foreign exchange and assumes an effective tax rate of 25%, 2026 G&A ex-items is expected to be approximately $43 million to $45 million, and full-year 2026 capital expenditures excluding CapEx for rebuilding the U.K. facility are expected to be in the range of $14 million to $16 million.

Core Laboratories Financial Statement Overview

Summary

Balance sheet strength is a key positive (materially improved leverage and steadily growing equity), and free cash flow is positive with an improvement in the latest period. Offsetting this, TTM revenue fell sharply and profitability compressed versus prior years, indicating weak near-term operating momentum and reduced return metrics.

Income Statement

45Neutral

Balance Sheet

78Positive

Cash Flow

62Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue516.74M526.52M523.85M509.79M489.74M470.25M
Gross Profit91.29M94.28M88.37M94.05M78.92M83.84M
EBITDA53.90M71.12M73.51M70.42M58.69M63.78M
Net Income15.56M29.67M31.40M36.67M19.45M19.73M
Balance Sheet
Total Assets593.52M584.01M590.41M586.39M578.35M580.85M
Cash, Cash Equivalents and Short-Term Investments21.38M22.70M19.16M15.12M15.43M17.70M
Total Debt161.97M164.02M180.14M215.38M222.39M250.26M
Total Liabilities309.43M311.80M332.67M356.59M389.40M419.85M
Stockholders Equity277.97M265.99M251.99M224.81M184.26M156.45M
Cash Flow
Free Cash Flow20.89M22.29M43.36M14.21M14.74M23.04M
Operating Cash Flow24.69M37.03M56.39M24.79M24.96M36.58M
Investing Cash Flow-14.27M-2.23M-6.39M-6.65M-3.86M-10.22M
Financing Cash Flow-14.68M-31.25M-45.96M-18.45M-23.38M-22.46M

Core Laboratories Technical Analysis

Technical Analysis SentimentNegative
Last Price9.11

Price Trends

50DMA10.37Negative
100DMA10.99Negative
200DMA13.33Negative

Market Momentum

MACD-0.38Positive
RSI38.17Neutral
STOCH23.13Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLB, the sentiment is Negative. The current price of 9.11 is below the 20-day moving average (MA) of 9.71, below the 50-day MA of 10.37, and below the 200-day MA of 13.33, indicating a bearish trend. The MACD of -0.38 indicates Positive momentum. The RSI at 38.17 is Neutral, neither overbought nor oversold. The STOCH value of 23.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLB.

Core Laboratories Risk Analysis

Core Laboratories disclosed 17 risk factors in its most recent earnings report. Core Laboratories reported the most risks in the "Finance & Corporate" category.

  • Finance & Corporate5
  • Tech & Innovation3
  • Legal & Regulatory2
  • Production2
  • Ability to Sell1
  • Macro & Political4
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Core Laboratories Peers Comparison

Overall Rating

UnderperformOutperform
Sector (65)

Financial Indicators

CLB against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
FTIFTI76Outperform$25.76B20.4538.54%0.30%7.95%42.53%
WFRDWFRD73Outperform$6.27B15.3622.51%1.27%-5.65%0.77%
BKRBKR66Neutral$49.10B16.8714.83%1.86%3.71%0.14%
HALHAL66Neutral$27.94B14.1318.46%2.01%1.53%58.46%
Sector *65Neutral$15.17B7.614.09%5.20%3.87%-62.32%
XPROXPRO58Neutral$1.51B1154.700.10%―-4.75%-97.74%
CLBCLB55Neutral$417.45M26.795.73%0.44%-0.15%-44.32%

* Energy Sector Average

Performance Comparison

0%50%CLBBKRFTIHALWFRDXPRODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CLB and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CLBCore Laboratories N.V.9.11-5.98-39.62%
BKRBaker Hughes Company49.442.304.88%
FTITechnipFMC66.2623.6755.58%
HALHalliburton Company33.787.6929.47%
WFRDWeatherford International Plc86.4516.3123.25%
XPROExpro Group Holdings N.V.13.510.050.37%

Core Laboratories Corporate Events

Business Operations and StrategyStock BuybackDividendsFinancial Disclosures

Core Laboratories Posts Solid Q3 2026 Revenue Growth

Positive
Oct 28, 2026

On October 28, 2026, Core Laboratories reported third quarter 2026 revenue of $132.1 million, up 6% sequentially but down 2% year over year, with GAAP operating income of $12.1 million and earnings per share of $0.12. On an adjusted basis, operating...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026